Induction of Stable Drug Resistance in Human Breast Cancer Cells Using a Combinatorial Zinc Finger Transcription Factor Library

Combinatorial libraries of artificial zinc-finger transcription factors (ZF-TFs) provide a robust tool for inducing and understanding various functional components of the cancer phenotype. Herein, we utilized combinatorial ZF-TF library technology to better understand how breast cancer cells acquire resistance to fulvestrant, a clinically important anti-endocrine therapeutic agent. From a diverse collection of nearly 400,000 different ZF-TFs, we isolated six ZF-TF library members capable of inducing stable, long-term anti-endocrine drug-resistance in two independent estrogen receptor-positive breast cancer cell lines. Comparative gene expression profile analysis of the six different ZF-TF-transduced breast cancer cell lines revealed five distinct clusters of differentially expressed genes. One cluster was shared among all 6 ZF-TF-transduced cell lines and therefore constituted a common fulvestrant-resistant gene expression signature. Pathway enrichment-analysis of this common fulvestrant resistant signature also revealed significant overlap with gene sets associated with an estrogen receptor-negative-like state and with gene sets associated with drug resistance to different classes of breast cancer anti-endocrine therapeutic agents. Enrichment-analysis of the four remaining unique gene clusters revealed overlap with myb-regulated genes. Finally, we also demonstrated that the common fulvestrant-resistant signature is associated with poor prognosis by interrogating five independent, publicly available human breast cancer gene expression datasets. Our results demonstrate that artificial ZF-TF libraries can be used successfully to induce stable drug-resistance in human cancer cell lines and to identify a gene expression signature that is associated with a clinically relevant drug-resistance phenotype.

[1]  Ben S. Wittner,et al.  Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor , 2009, Proceedings of the National Academy of Sciences.

[2]  Pilar Blancafort,et al.  In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. , 2004, Journal of molecular biology.

[3]  Fabio Stossi,et al.  Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. , 2004, Endocrinology.

[4]  J. Rushton,et al.  Positive and Negative Determinants of Target Gene Specificity in Myb Transcription Factors*[boxs] , 2004, Journal of Biological Chemistry.

[5]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[6]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[7]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[8]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[9]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[10]  N. Pavletich,et al.  Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A , 1991, Science.

[11]  Jiwon Kim,et al.  Toward a functional annotation of the human genome using artificial transcription factors. , 2003, Genome research.

[12]  C. Case,et al.  Validated Zinc Finger Protein Designs for All 16 GNN DNA Triplet Targets* , 2002, The Journal of Biological Chemistry.

[13]  D. Sgroi,et al.  HOXB13 promotes ovarian cancer progression , 2007, Proceedings of the National Academy of Sciences.

[14]  R. Kumar,et al.  Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. , 1998, Endocrinology.

[15]  W. Seol,et al.  Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library. , 2004, Nucleic acids research.

[16]  A. Iafrate,et al.  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.

[17]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[18]  C. Pabo,et al.  DNA recognition by Cys2His2 zinc finger proteins. , 2000, Annual review of biophysics and biomolecular structure.

[19]  A. Klug,et al.  Repetitive zinc-binding domains in the protein transcription factor IIIA fromXenopus oocytes , 2001 .

[20]  Young Do Kwon,et al.  Human zinc fingers as building blocks in the construction of artificial transcription factors , 2003, Nature Biotechnology.

[21]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[22]  Kyung-Soon Park,et al.  Phenotypic Alteration and Target Gene Identification Using Combinatorial Libraries of Zinc Finger Proteins in Prokaryotic Cells , 2005, Journal of bacteriology.

[23]  Sridhar Ramaswamy,et al.  Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort , 2008, Clinical Cancer Research.

[24]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Kyung-Soon Park,et al.  Phenotypic alteration of eukaryotic cells using randomized libraries of artificial transcription factors , 2003, Nature Biotechnology.

[26]  Yu Shyr,et al.  A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance , 2011, Clinical Cancer Research.

[27]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[28]  Pilar Blancafort,et al.  Scanning the human genome with combinatorial transcription factor libraries , 2003, Nature Biotechnology.

[29]  Xin Wang,et al.  Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. , 2008, Cancer research.

[30]  Thies Schroeder,et al.  Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. , 2008, Cancer research.

[31]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Seong-Il Lee,et al.  Identification and Use of Zinc Finger Transcription Factors That Increase Production of Recombinant Proteins in Yeast and Mammalian Cells , 2008, Biotechnology progress.

[33]  A Klug,et al.  Repetitive zinc‐binding domains in the protein transcription factor IIIA from Xenopus oocytes. , 1985, The EMBO journal.

[34]  C. D. Salcido,et al.  Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes , 2008, British Journal of Cancer.

[35]  D. Erdmann,et al.  Genetic reprogramming of tumor cells by zinc finger transcription factors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[37]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[38]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[39]  J. Joung,et al.  A bacterial two-hybrid selection system for studying protein-DNA and protein-protein interactions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Seol,et al.  Artificial Transcription Factors Increase Production of Recombinant Antibodies in Chinese Hamster Ovary Cells , 2005, Biotechnology Letters.

[41]  N Andrieu,et al.  Strong association between c-myb and oestrogen-receptor expression in human breast cancer. , 1990, Oncogene.

[42]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[43]  A. Sahin,et al.  Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. , 2002, International journal of oncology.

[44]  Simon C Barry,et al.  Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells , 2007, Proceedings of the National Academy of Sciences.

[45]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[46]  D. Erdmann,et al.  Modulation of drug resistance by artificial transcription factors , 2008, Molecular Cancer Therapeutics.